Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP14012 + naproxen
- Development stage
- Phase 1
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWP14012 + naproxen is a combination therapy consisting of DWP14012 (fexuprazan), a potassium-competitive acid blocker (P-CAB), and naproxen, a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid class. Fexuprazan acts by reversibly and competitively inhibiting gastric H^+/K^+-ATPase, leading to suppression of gastric acid secretion, while naproxen is an inhibitor of cyclooxygenase enzymes, primarily COX-1 and COX-2, reducing inflammation and pain. The combination is under investigation to reduce gastric and duodenal ulcer risk caused by NSAID use, leveraging the gastroprotective action of fexuprazan with the analgesic and anti-inflammatory properties of naproxen. DWP14012 (fexuprazan) is developed by Daewoong Pharmaceutical.
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on DWP14012 + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP14012 + naproxen.